



Exelixis Announces March 10 Webcast of Presentation at the Barclays Capital Global Healthcare Conference

March 5, 2009

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 5, 2009-- Exelixis, Inc. (Nasdaq:EXEL) announced today that Michael Morrissey, PhD, the company's President of Research & Development, will present at the Barclays Capital Global Healthcare Conference at 4:45 p.m. ET/1:45 p.m. PT on Tuesday, March 10, 2009. Dr. Morrissey will discuss the company's corporate strategy, financial outlook, and development pipeline.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at www.exelixis.com.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, GlaxoSmithKline, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's web site at www.exelixis.com.

Exelixis and the Exelixis logo are registered U.S. trademarks.

Source: Exelixis, Inc.

Exelixis, Inc.

Investor Contact:

Charles Butler, 650-837-7277

Senior Director

Corporate Communications

& Investor Relations

[*cbutler@exelixis.com*](mailto:cbutler@exelixis.com)

Media Contact:

Soleil Maxwell Harrison, 650-837-7012

Senior Manager

Corporate Communications

[*sharrison@exelixis.com*](mailto:sharrison@exelixis.com)